Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
AKRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.86 - $58.40
Previous CloseN/A
Volume136.04K
Average Volume (3M)1.18M
Market Cap
$2.77B
Enterprise Value$1.26B
Total Cash (Recent Filing)$598.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 20, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding79,620,125
10 Day Avg. Volume1,617,731
30 Day Avg. Volume1,177,397
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.08
Forecast
1Y Price Target
$74.00Price Target Upside107.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Akero Therapeutics News
See All AKRO News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Phase 3 SYNCHRONY program for MASH is advancing at full speed, with important data expected to support accelerated approval for EFX.
Financial StabilityAkero reported a cash position of $797.8M, showing financial stability.
Therapeutic PotentialAkero's recent clinical success in its SYMMETRY trial positions efruxifermin as a potential best-in-disease therapy for severe F4C MASH patients.
Bears Say
Clinical Data ExpectationsThe SYNCHRONY Histology study is designed to support an NDA under accelerated approval by measuring key clinical outcomes in MASH patients.
Competition And Market InterestStrategic interest for Akero’s FGF21 analog remains high, particularly as large biopharma look to build out their respective MASH portfolios.
---
Ownership Overview
3.25% Insiders
22.58% Mutual Funds
37.76% Other Institutional Investors
24.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKRO FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was $17.86 and its highest was $58.40 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Akero Therapeutics Inc’s market cap is $2.77B.
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is May 20, 2025 which is in 37 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Feb 28, 2025. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.161 by $0.171.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -0.97.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 79,620,125 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.161. Following the earnings report the stock price went up 2.869%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Currently, no hedge funds are holding shares in AKRO
---
Akero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (107.52% Upside)
$74.00 (107.52% Upside)
Blogger Sentiment
Bullish
AKRO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 455.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $18.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.30%
12-Months-Change
Fundamentals
Return on Equity
-39.22%
Trailing 12-Months
Asset Growth
42.33%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
---
AKRO Stock 12 Month Forecast
Average Price Target
$74.00
▲(107.52% Upside)
Technical Analysis
PTC Therapeutics
―
Soleno Therapeutics
―
Crispr Therapeutics AG
―
Rhythm Pharmaceuticals
―
Springworks Therapeutics
―
Best Analysts Covering AKRO
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+33.61%
reiterated a buy rating last month
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +33.61% per trade.
---